Fidelity International
BCAX

Fidelity International’s Bicara Therapeutics BCAX Stock Holding History

Fidelity International’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Sell
679,904
-78,589
-10% -$1.35M 0.01% 548
2025
Q4 		$12.8M Sell
758,493
-45,260
-6% -$773K 0.01% 548
2025
Q3 		$12.7M Sell
803,753
-210,100
-21% -$2.35M 0.01% 537
2025
Q2 		$9.42M Hold
1,013,853
– – 0.01% 551
2025
Q1 		$13.2M Hold
1,013,853
– – 0.01% 491
2024
Q4 		$17.7M Hold
1,013,853
– – 0.02% 462
2024
Q3 		$25.8M Buy
+1,013,853
New +$25.9M 0.02% 425

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity International's BCAX Position: Q1 2026 in Review

Fidelity International reduced its Bicara Therapeutics (BCAX) stake by 10% in Q1 2026, selling an estimated $1.35M and leaving 679,904 shares worth $13.5M. The position accounts for 0.01% of the portfolio, ranked #548.

Fidelity International first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $25.8M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Fidelity International held 679,904 shares of Bicara Therapeutics worth $13.5M as of Q1 2026.
  • Fidelity International sold 78,589 Bicara Therapeutics shares in Q1 2026, an estimated $1.35M.
  • Bicara Therapeutics made up 0.01% of Fidelity International's portfolio in Q1 2026, its #548 holding.
  • Fidelity International first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Fidelity International's Bicara Therapeutics position peaked at $25.8M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.